olmesartan has been researched along with tacrine in 3 studies
Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (tacrine) | Trials (tacrine) | Recent Studies (post-2010) (tacrine) |
---|---|---|---|---|---|
841 | 185 | 554 | 2,141 | 161 | 643 |
Protein | Taxonomy | olmesartan (IC50) | tacrine (IC50) |
---|---|---|---|
Chain A, ACETYLCHOLINESTERASE | Tetronarce californica (Pacific electric ray) | 0.0082 | |
Solute carrier family 22 member 2 | Homo sapiens (human) | 0.68 | |
Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.1401 | |
Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.1691 | |
Amyloid-beta precursor protein | Homo sapiens (human) | 0.0456 | |
Cytochrome P450 1A2 | Homo sapiens (human) | 0.7875 | |
Cytochrome P450 2E1 | Homo sapiens (human) | 0.075 | |
Cholinesterase | Homo sapiens (human) | 0.0545 | |
Acyl-CoA desaturase 1 | Rattus norvegicus (Norway rat) | 0.047 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.517 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 6.6 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 6.6 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 6.6 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.1084 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 6.6 | |
Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.0457 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 0.3 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 6.6 | |
Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.0457 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.078 | |
Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | 0.1957 | |
Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.0835 | |
Amine oxidase [flavin-containing] A | Bos taurus (cattle) | 0.047 | |
Acetylcholinesterase | Mus musculus (house mouse) | 0.1143 | |
Acetylcholinesterase | Homo sapiens (human) | 0.2576 | |
Acetylcholinesterase | Bos taurus (cattle) | 0.1848 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.517 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 0.1143 | |
Acetylcholinesterase | Rattus norvegicus (Norway rat) | 0.2097 | |
Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | 0.042 | |
Cholinesterase | Equus caballus (horse) | 0.1103 | |
Histamine N-methyltransferase | Rattus norvegicus (Norway rat) | 0.11 | |
Cholinesterase | Mus musculus (house mouse) | 0.0625 | |
Acetylcholine receptor subunit epsilon | Homo sapiens (human) | 0.044 | |
Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 6.3 | |
Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 6.3 | |
Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | 0.267 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.1 | |
Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | 0.0995 | |
Carboxylic ester hydrolase | Equus caballus (horse) | 0.0143 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
3 other study(ies) available for olmesartan and tacrine
Article | Year |
---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |